Combination therapy with the type II anti-CD20 antibody obinutuzumab

References

• Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122:981–987.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–3732.
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group hematology and oncology study. J Clin Oncol. 2007;25:1986–1992.
   PubMed Web of Science ®Google Scholar
• Salles G, Mounier N, de Guilbert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients results of the GELA-GOELAMS FL2000 study. Blood. 2008;112:4824–4831.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;28:4579–4586.
   Google Scholar
• Chao MP. Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma - novel and emerging therapies. Cancer Manag Res. 2013;5:251–269.
   PubMedGoogle Scholar
• Medscape [Internet]; Vinjamaram S. Non-Hodgkin lymphoma treatment & management: approach considerations, management of indolent NHL, management of aggressive NHL; 2016 Sep 22 [2016 Apr 1]. Available at http://emedicine.medscape.com/article/203399-treatment#d7
   Google Scholar
• Cohen JB, Flowers CR. Optimal disease surveillance strategies in non-Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2014;2014:481–487.
   PubMed Web of Science ®Google Scholar
• Zappasodi R, De Braud F, Di Nicola M. Lymphoma immunotherapy: current status. Front Immunol. 2015;6:448.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Muller C, Zeynalova S, et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 2014;123:640–646.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network [Internet]. NCCN clinical practice guidelines in oncology (NCCN Guidelines®): non-Hodgkin’s lymphomas, version 4.2014; 2014 Aug 22 [cited 2017 Feb 6. Available at https://www.nccn.org/about/nhl.pdf
   Google Scholar
• Pfreundschuh M. Increased rituximab (R) doses and effect on risk of elderly male patients with aggressive CD20 B-cell lymphomas: results from the SEXIE-RCHOP-14 trial of the DSHNHL. J Clin Oncol. 2014;32:539s.
   Web of Science ®Google Scholar
• Lugtenburg P, de Nully Brown P, van der Holt B, et al. Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: results from a HOVON-Nordic Lymphoma Group study. J Clin Oncol. 2016;34:suppl, abstract 7504.
   Web of Science ®Google Scholar
• Wang Y, Probin V, Zhou D. Cancer therapy-induced residual bone marrow injury-mechanisms of induction and implication for therapy. Curr Cancer Ther Rev. 2006;2:271–279.
   PubMedGoogle Scholar
• Bachy E, Salles G. Are we nearing an era of chemotherapy-free management of indolent lymphoma? Clin Cancer Res. 2014;20:5226–5239.
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–195.
   PubMed Web of Science ®Google Scholar
• An X, Tiwari AK, Sun Y, et al. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010;34:1255–1268.
   PubMed Web of Science ®Google Scholar
• GAZYVA®. US prescribing information. cited 2017 Apr. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125486s010lbledt.pdf
   Google Scholar
• GAZYVARO®. Summary of product characteristics. [cited 2017 Apr]. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002799/WC500171594.pdf
   Google Scholar
• Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393–4402.
   PubMed Web of Science ®Google Scholar
• Niederfellner G, Lammens A, Mundigl O, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood. 2011;118:358–367.
   PubMed Web of Science ®Google Scholar
• Klein C, Lammens A, Schafer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013;5:22–33.
   PubMed Web of Science ®Google Scholar
• Delves PJ, Martin SJ, Burton DR, et al. Ontogeny and phylogeny. Roitt’s essential immunology. 12th. 283–310. Chichester (UK): Wiley-Blackwell; 2011.
   Google Scholar
• Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12:2031–2042.
   PubMed Web of Science ®Google Scholar
• Herter S, Birk MC, Klein C, et al. Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol. 2014;192:2252–2260.
   PubMed Web of Science ®Google Scholar
• Golay J, Da Roit F, Bologna L, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013;122:3482–3491.
   PubMed Web of Science ®Google Scholar
• Suresh T, Lee LX, Joshi J, et al. New antibody approaches to lymphoma therapy. J Hematol Oncol. 2014;7:58.
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177:362–371.
   PubMed Web of Science ®Google Scholar
• Tobinai K, Klein C, Oya N, et al. A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther. 2017;34:324–356.
   PubMed Web of Science ®Google Scholar
• Lim SH, Vaughan AT, Ashton-Key M, et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood. 2011;118:2530–2540.
   PubMed Web of Science ®Google Scholar
• Tipton TR, Roghanian A, Oldham RJ, et al. Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies. Blood. 2015;125:1901–1909.
   PubMed Web of Science ®Google Scholar
• Beers SA, French RR, Chan HT, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010;115:5191–5201.
   PubMed Web of Science ®Google Scholar
• Honeychurch J, Alduaij W, Azizyan M, et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood. 2012;119:3523–3533.
   PubMed Web of Science ®Google Scholar
• Cheadle EJ, Sidon L, Dovedi SJ, et al. The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab. Br J Haematol. 2013;162:842–845.
   PubMed Web of Science ®Google Scholar
• Herting F, Friess T, Bader S, et al. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leuk Lymphoma. 2014;55:2151–2160.
   PubMed Web of Science ®Google Scholar
• Salles G, Morschhauser F, Lamy T, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012;119:5126–5132.
   PubMed Web of Science ®Google Scholar
• Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31:2912–2919.
   PubMed Web of Science ®Google Scholar
• Cartron G, de Guibert S, Dilhuydy MS, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014;124:2196–2202.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Goy A, Offner FC, et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol. 2015;33:3467–3474.
   PubMed Web of Science ®Google Scholar
• Ogura M, Tobinai K, Hatake K, et al. Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 2012;104:105–110.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Flynn JM, Kipps TJ, et al. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood. 2016;127:79–86.
   PubMed Web of Science ®Google Scholar
• Radford J, Davies A, Cartron G, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood. 2013;122:1137–1143.
   PubMed Web of Science ®Google Scholar
• Dyer MJS, Grigg AP, Gonzàlez Dìaz M, et al. Obinutuzumab (GA101) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or bendamustine for the first-line treatment of follicular non-Hodgkin lymphoma: final results from the maintenance phase of the phase Ib GAUDI study. Presented at: 56th Annual Meeting and Exposition of the American Society of Hematology; 2014 Dec 6–9; San Francisco, CA.
   Google Scholar
• Zelenetz AD, Mobasher M, Costa LJ, et al. Safety and efficacy of obinutuzumab (GA101) plus CHOP chemotherapy in first-line advanced diffuse large B-cell lymphoma: results from the phase 2 Gather study (GAO4915g). Blood. 2013;122:1820.
   Google Scholar
• Brown JR, O’Brien S, Kingsley CD, et al. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood. 2015;125:2779–2785.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101–1110.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Bosch F, et al. Updated survival analysis from the CLL11 study: obinutuzumab versus rituximab in chemoimmunotherapy-treated patients with chronic lymphocytic leukemia. Blood. 2015;126:1733.
   PubMed Web of Science ®Google Scholar
• Marcus RE, Davies AJ, Ando K, et al. Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: primary results of the randomized phase 3 GALLIUM study. Blood. 2016;128:6.
   Google Scholar
• Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017 Aug 10;DOI:10.1200/JCO.2017.73.3402
   Web of Science ®Google Scholar
• Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17:1081–1093.
   PubMed Web of Science ®Google Scholar
• Trněný M, Bouabdallah K, Dueck G, et al. Obinutuzumab plus bendamustine versus bendamustine alone in patients with rituximab-refractory follicular lymphoma: results from the GADOLIN study. Haematologica. 2016;101:S440.
   Web of Science ®Google Scholar
• Cheson BD, Trněný M, Bouabdallah K, et al. Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma: updated results of the GADOLIN study. Presented at: 58th Annual Meeting and Exposition of the American Society of Hematology; 2016 Dec 3–6; San Diego, CA.
   Google Scholar
• Salles GA, Morschhauser F, Solal-Céligny P, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31:2920–2926.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Assouline SE, Stewart DA, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood. 2012;119:5118–5125.
   PubMed Web of Science ®Google Scholar
• Davies A, Merli F, Mihaljević B, et al. Efficacy and safety of subcutaneous versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017;4:e272–e282.
   PubMed Web of Science ®Google Scholar
• Lugtenburg P, Avivi I, Berenschot H, et al. Rituximab SC and IV plus CHOP show similar efficacy and safety in the randomised MabEase study in first-line DLBCL. Haematol Oncol. 2017;35(suppl s2):185-186.
   Google Scholar
• Ritgen M, Langerak A, Goede V, et al. Quantitative MRD is prognostic for progression-free and overall survival in elderly patients receiving chlorambucil alone or with obinutuzumab/rituximab: a prospective analysis of the GCLLSG CLL11 study. Presented at: 21st Congress of the European Hematology Association; 2016 Jun 9–12; Copenhagen, Denmark.
   Google Scholar
• Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010;116:106–114.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26:204–210.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Trask PC, Gribben JG, et al. Primary results of the health-related quality of life assessment from the phase III GADOLIN study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory, indolent non-Hodgkin lymphoma. Presented at: 57th Annual Meeting & Exposition of the American Society of Hematology; 2015 Dec 5–8; Orlando, FL.
   Google Scholar
• Pott C, Belada D, Danesi N, et al. Analysis of minimal residual disease in follicular lymphoma patients in GADOLIN, a phase III study of obinutuzumab plus bendamustine versus bendamustine in relapsed/refractory indolent non-Hodgkin lymphoma. Blood. 2015;126:3978.
   Web of Science ®Google Scholar
• Pott C, Belada D, Danesi N, et al. Minimal residual disease and outcomes in relapsed/refractory follicular lymphoma (FL) in the phase III GADOLIN trial of obinutuzumab and bendamustine vs bendamustine. Haematol Oncol. 2017;35(suppl s2):216–217.
   Google Scholar
• Freeman CL, Morschhauser F, Sehn L, et al. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood. 2015;126:2646–2649.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Mobasher M, Costa LJ, et al. Safety and efficacy of obinutuzumab (GA101) plus CHOP chemotherapy in first-line advanced diffuse large B-cell lymphoma: results from the phase 2 Gather study (GAO4915g). Blood. 2013;122:1820.
   Web of Science ®Google Scholar
• Tsujimura H, Kumagai K, Teshima T, et al. Safety and tolerability of obinutuzumab (GA101) with shorter duration of infusion in Japanese patients with previously untreated CD20-positive B-cell non-Hodgkin’s lymphoma (NHL) – comparison with GAO4915g (GATHER) and BO21005 (GOYA) studies. Blood. 2016;128:5389.
   Web of Science ®Google Scholar
• Shaffer AL 3rd, Young RM, Staudt LM. Pathogenesis of human B cell lymphomas. Annu Rev Immunol. 2012;30:565–610.
   PubMed Web of Science ®Google Scholar
• Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116:205–219.
   PubMed Web of Science ®Google Scholar
• Llambi F, Moldoveanu T, Tait SW, et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell. 2011;44:517–531.
   PubMed Web of Science ®Google Scholar
• Itchaki G, Brown JR. The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia. Ther Adv Hematol. 2016;7:270–287.
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–208.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Fowler NH, Wang ML. Breakthrough therapies in B-cell non-Hodgkin lymphoma. Ann Oncol. 2016;27:778–787.
   PubMed Web of Science ®Google Scholar
• Vogler M, Dinsdale D, Dyer MJ, et al. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol. 2013;163:139–142.
   PubMed Web of Science ®Google Scholar
• Touzeau C, Dousset C, Le Gouill S, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28:210–212.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Eichhorst B, Schetelig J, et al. Ventoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768–778.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322.
   PubMed Web of Science ®Google Scholar
• King AC, Peterson TJ, Horvat TZ, et al. Venetoclax. Ann Pharmacother. 2017;51:410–416.
   PubMed Web of Science ®Google Scholar
• Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35:826–833.
   PubMed Web of Science ®Google Scholar
• Sampath D, Herter S, Ingalla E, et al. Combination of the glycoengineered type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor ABT-199 (GDC-0199) results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies. Presented at: 21st Congress of the European Hematology Association; 2016 Jun 9–12; Copenhagen, Denmark.
   Google Scholar
• Flinn IW, Brunvand M, Choi MY, et al. Safety and efficacy of a combination of venetoclax (GDC-0199/ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia–results from a phase 1b study (GP28331). Blood. 2015;126:494.
   PubMed Web of Science ®Google Scholar
• Fischer K, Al-Sawaf O, Fink AM, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129:2701–2705.
   Google Scholar
• Casulo C, Jacobsen ED, Van Eygen K, et al. Preliminary safety, pharmacokinetics, and pharmacodynamics of duvelisib plus rituximab or obinutuzumab in patients with previously untreated CD20+ follicular lymphoma. J Clin Oncol. 2016;34:suppl, abstract e19052.
   Web of Science ®Google Scholar
• Till BG, Park SI, Popplewell LL, et al. Safety and clinical activity of atezolizumab (anti-PDL1) in combination with obinutuzumab in patients with relapsed or refractory non-Hodgkin lymphoma. Blood. 2015;126:5104.
   Web of Science ®Google Scholar
• Fowler N, Pinto RM, Cheah CY, et al. A phase I study of lenalidomide plus a next generation anti-CD20 antibody, obinutuzumab, in relapsed indolent lymphoma. Blood. 2015;126:2742.
   Web of Science ®Google Scholar
• Saha MN, Qiu L, Chang H. Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol. 2013;6:23.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Ichikawa A, Saito H, et al. Overexpression of the MDM2 oncogene in leukemia and lymphoma. Leuk Lymphoma. 1996;21:391–397, color plates XVI following 5.
   PubMed Web of Science ®Google Scholar
• Pagnano KB, Vassallo J, Lorand-Metze I, et al. p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin’s lymphomas. Am J Hematol. 2001;67:84–92.
   PubMed Web of Science ®Google Scholar
• Klein C, Vassilev LT. Targeting the p53-MDM2 interaction to treat cancer. Br J Cancer. 2004;91:1415–1419.
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844–848.
   PubMed Web of Science ®Google Scholar
• Ding Q, Zhang Z, Liu JJ, et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem. 2013;56:5979–5983.
   PubMed Web of Science ®Google Scholar
• Higgins B, Glenn K, Walz A, et al. Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach. Clin Cancer Res. 2014;20:3742–3752.
   PubMed Web of Science ®Google Scholar
• Yee K, Martinelli G, Vey N, et al. Phase 1/1b study of RG7388, a potent MDM2 antagonist, in acute myelogenous leukemia (AML) patients (pts). Blood. 2014;124:116.
   Google Scholar
• Herting F, Herter S, Friess T, et al. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388). Eur J Haematol. 2016;97:461–470.
   PubMed Web of Science ®Google Scholar
• Herting F, Friess T, Umana P, et al. The triple combination of the CD20 antibody obinutuzumab with the Bcl-2 inhibitor venetoclax (GDC-199) and the MDM2 inhibitor idasanutlin results in superior efficacy and long term response in wildtype p53 NHL tumor models. Blood. 2016;128:4178.
   Web of Science ®Google Scholar
• Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120:1175–1184.
   PubMed Web of Science ®Google Scholar
• Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014;14:219–232.
   PubMed Web of Science ®Google Scholar
• Wu J, Liu C, Tsui ST, et al. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol. 2016;9:80.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms. Pharmacol Res. 2016;113:395–408.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Sagiv-Barfi I, Rafiq S, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 2014;123:1957–1960.
   PubMed Web of Science ®Google Scholar
• Ng PP, Lu DK, Sukbuntherng J, et al. Ibrutinib enhances the activity of anti-CD20 antibodies in an MCL mouse model: effect of drug at clinically relevant concentrations on ADCC and ADCP. Blood. 2015;126:3998.
   Web of Science ®Google Scholar
• Duong MN, Matera EL, Mathe D, et al. Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies. MAbs. 2015;7:192–198.
   PubMed Web of Science ®Google Scholar
• Ysebaert L, Klein C, Quillet-Mary A. CLL cells from ibrutinib-induced lymphocytosis of relapsed/refractory chronic lymphocytic leukemia patients are responsive to obinutuzumab, but not rituximab, ex vivo. Blood. 2015;126:4157.
   Web of Science ®Google Scholar
• Herter S, Sagiv-Barfi I, Chester C, et al. Obinutuzumab (GA101) is less prone to antagonism of immune effector function by ibrutinib than rituximab in vitro and in vivo. Blood. 2014;124:1765.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting Btk with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
   PubMed Web of Science ®Google Scholar
• Jaglowski SM, Jones JA, Nagar V, et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015;126:842–850.
   PubMed Web of Science ®Google Scholar
• Wang M, Hagemeister F, Westin JR, et al. Ibrutinib and rituximab are an efficacious and safe combination in relapsed mantle cell lymphoma: preliminary results from a phase II clinical trial. Blood. 2014;124:627.
   Web of Science ®Google Scholar
• Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15:1090–1099.
   PubMed Web of Science ®Google Scholar
• Fowler N, Nastoupil L, de Vos S, et al. Ibrutinib plus rituximab in treatment-naive patients with follicular lymphoma: results from a multicenter, phase 2 study. Blood. 2015;126:470.
   Web of Science ®Google Scholar
• Flinn I, Moreno C, Gill DS, et al. Randomized, multicenter, open-label, phase 3 study of the BTK inhibitor ibrutinib in combination with obinutuzumab vs. chlorambucil in combination with obinutuzumab in patients with treatment-naïve CLL/SLL (PCYC-1130): iLLUMINATE. J Clin Oncol. 2015;33:suppl, abstract TPS7095.
   Web of Science ®Google Scholar
• Yasuhiro T, Yoshizawa T, Hotta S, et al. ONO-4059, a novel oral Bruton’s tyrosine kinase (Btk) inhibitor that demonstrates potent pharmacodynamic activity through phosphorylated Btk (P-Btk) inhibition, in addition to effective anti-tumour activity in a TMD-8 (DLBCL) xenograft model. Cancer Res. 2013;73(8Suppl):abstract2452.
   Google Scholar
• Walter HS, Rule SA, Dyer MJ, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127:411–419.
   PubMed Web of Science ®Google Scholar
• Yasuhiro T, Sawada W, Klein C, et al. Anti-tumor efficacy study of the Bruton’s tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab. Leuk Lymphoma. 2017;58:699–707.
   PubMed Web of Science ®Google Scholar
• Harrington BK, Gardner HL, Izumi R, et al. Preclinical evaluation of the novel BTK inhibitor acalabrutinib in canine models of B-cell non-Hodgkin lymphoma. PLoS One. 2016;11:e0159607.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323–332.
   PubMed Web of Science ®Google Scholar
• Li N, Sun Z, Liu Y, et al. BGB-3111 is a novel and highly selective Bruton’s tyrosine kinase (BTK) inhibitor. Cancer Res. 2015;75(15Suppl):abstract2597.
   Google Scholar
• Tam C, Grigg AP, Opat S, et al. The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial. Blood. 2015;126:832.
   Web of Science ®Google Scholar
• Balakrishnan K, Peluso M, Fu M, et al. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia. 2015;29:1811–1822.
   PubMed Web of Science ®Google Scholar
• Durand CA, Hartvigsen K, Fogelstrand L, et al. Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol. 2009;183:5673–5684.
   PubMed Web of Science ®Google Scholar
• Bilancio A, Okkenhaug K, Camps M, et al. Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood. 2006;107:642–650.
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117:591–594.
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3ʹ-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118:3603–3612.
   PubMed Web of Science ®Google Scholar
• Herman SE, Lapalombella R, Gordon AL, et al. The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood. 2011;117:4323–4327.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123:3406–3413.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008–1018.
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood. 2015;126:2686–2694.
   PubMed Web of Science ®Google Scholar
• Herter S, Palazzo A, Bacac M, et al. The PI3K delta selective inhibitor idelalisib minimally interferes with immune effector function and B cell depletion mediated by obinutuzumab (GA101) and rituximab. Blood. 2014;124:3342.
   PubMed Web of Science ®Google Scholar
• ZYDELIG® (idelalisib). US prescribing information. [cited 2017 Apr]. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206545lbl.pdf
   Google Scholar
• ZYDELIG® (idelalisib). Summary of product characteristics. [cited 2017 Apr]. Available at https://www.medicines.org.uk/emc/medicine/29201
   Google Scholar
• OncLive [Internet]. FDA halts six idelalisib combination studies; 2016 Mar 15 [cited 2017 Feb 12]. Available at http://www.onclive.com/web-exclusives/fda-halts-six-idelalisib-combination-studies
   Google Scholar
• Winkler DG, Faia KL, DiNitto JP, et al. PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013;20:1364–1374.
   PubMed Web of Science ®Google Scholar
• Dong S, Guinn D, Dubovsky JA, et al. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood. 2014;124:3583–3586.
   PubMed Web of Science ®Google Scholar
• Flinn I, Oki Y, Patel M, et al. A phase 1 evaluation of duvelisib (IPI-145), a PI3K-δ,γ inhibitor, in patients with relapsed/refractory iNHL. Blood. 2014;124:802.
   Web of Science ®Google Scholar
• Fowler NH, Pearlberg J, Brail LH, et al. FRESCO: a phase 2, randomized study of duvelisib plus rituximab vs R-CHOP in patients with relapsed/refractory follicular lymphoma who have progressed within 24 months of receiving an alkylator-based chemotherapy regimen. J Clin Oncol. 2016;34:suppl, abstract TPS7578.
   Google Scholar
• Blachly JS, Brown JR, Barrientos JC, et al. A phase 1b trial of duvelisib, a PI3K-δ,γ inhibitor, in combination with obinutuzumab in patients with CLL/SLL previously treated with a Bruton’s tyrosine kinase inhibitor (BTKi). J Clin Oncol. 2015;33:suppl, abstract TPS7100.
   Web of Science ®Google Scholar
• Gockeritz E, Kerwien S, Baumann M, et al. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. Int J Cancer. 2015;137:2234–2242.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Flinn IW, Patel MR, et al. TGR-1202, a novel once daily PI3K-delta inhibitor, demonstrates clinical activity with a favorable safety profile in patients with CLL and B-cell lymphoma. Blood. 2015;126:4154.
   Web of Science ®Google Scholar
• Burris HA, Flinn I, Lunning MA, et al. Long-term follow-up of the PI3Kδ inhibitor TGR-1202 to demonstrate a differentiated safety profile and high response rates in CLL and NHL: integrated analysis of TGR-1202 monotherapy and combined with ublituximab. J Clin Oncol. 2016;34:suppl, abstract 7512.
   Web of Science ®Google Scholar
• Olejniczak SH, Stewart CC, Donohue K, et al. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest. 2006;35:93–114.
   PubMed Web of Science ®Google Scholar
• Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16:704–715.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Flinn I, Advani RH, et al. Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). J Clin Oncol. 2014;32:suppl, abstract 8519.
   Web of Science ®Google Scholar
• Zhao X, Lapalombella R, Joshi T, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood. 2007;110:2569–2577.
   PubMed Web of Science ®Google Scholar
• Pagel JM, Spurgeon SE, Byrd JC, et al. Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, for relapsed or refractory NHL patients. Br J Haematol. 2015;168:38–45.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Tarantolo SR, Bellam N, et al. Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Invest New Drugs. 2014;32:1213–1225.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Pagel JM, Awan FT, et al. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 2014;123:1302–1308.
   PubMed Web of Science ®Google Scholar
• Maddocks KJ, Pagel J, Byrd JC, et al. Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 ADAPTIR protein, in combination with rituximab in patients with chronic lymphocytic leukemia (CLL). Blood. 2014;124:4671.
   Google Scholar
• Robak T, Robak P. Anti-CD37 antibodies for chronic lymphocytic leukemia. Expert Opin Biol Ther. 2014;14:651–661.
   PubMed Web of Science ®Google Scholar
• Genentech, Inc. TECENTRIQ® (atezolizumab) injection, for intravenous use. South San Francisco, CA. 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761034s000lbl.pdf
   Google Scholar
• Zeldis JB, Knight R, Hussein M, et al. A review of the history, properties, and use of the immunomodulatory compound lenalidomide. Ann N Y Acad Sci. 2011;1222:76–82.
   PubMed Web of Science ®Google Scholar
• Stewart AK. Medicine. How thalidomide works against cancer. Science. 2014;343:256–257.
   PubMed Web of Science ®Google Scholar
• Celgene Corporation. REVLIMID® [(lenalidomide) capsules, for oral use. Summit (NJ). 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021880s034lbl.pdf
   Google Scholar
• Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009;84:553–559.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Shah B, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015;373:1835–1844.
   PubMed Web of Science ®Google Scholar
• Liang L, Zhao M, Zhu YC, et al. Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis. Ann Hematol. 2016;95:1473–1482.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Egyed M, Robak T, et al. Randomised phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial). Leukemia. 2017;31:1240–1243, Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Hagner PR, Man HW, Fontanillo C, et al. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood. 2015;126:779–789.
   PubMed Web of Science ®Google Scholar
• Chiu H, Hagner P, Pourdehnad M, et al. CC-122 exhibits potent anti-lymphoma activity in combination with obinutuzumab through cell autonomous and antibody dependent cell mediated cytotoxicity. Blood. 2015;126:4007.
   Web of Science ®Google Scholar
• Kobold S, Wiedemann G, Rothenfusser S, et al. Modes of action of TLR7 agonists in cancer therapy. Immunotherapy. 2014;6:1085–1095.
   PubMed Web of Science ®Google Scholar
• Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, et al. A TLR7 agonist enhances the anti-tumor efficacy of obinutuzumab through an NK cell/CD4 dependent mechanism in mice. Leukemia. 2017 Epub ahead of print
   Google Scholar
• Makkouk A, Chester C, Kohrt HE. Rationale for anti-CD137 cancer immunotherapy. Eur J Cancer. 2016;54:112–119.
   PubMed Web of Science ®Google Scholar
• Houot R, Kohrt H, Levy R. Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. Oncoimmunology. 2012;1:957–958.
   PubMed Web of Science ®Google Scholar
• Buechele C, Baessler T, Schmiedel BJ, et al. 4-1BB ligand modulates direct and rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia. Eur J Immunol. 2012;42:737–748.
   PubMed Web of Science ®Google Scholar
• Segal NH, Logan TF, Hodi FS, et al. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody. Clin Cancer Res. 2017;23:1929–1936.
   PubMed Web of Science ®Google Scholar
• Terszowski G, Klein C, Stern M. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity. J Immunol. 2014;192:5618–5624.
   PubMed Web of Science ®Google Scholar
• Terszowski G, Klein C, Schmied L, et al. How to outsmart NK cell tolerance. Oncoimmunology. 2015;4:e1016708.
   PubMed Web of Science ®Google Scholar
• Terszowski G, Crompton N, Goede V, et al. Association between KIR/HLA genotype and outcome in the CLL11 study of chronic lymphocytic leukemia (CLL) patients receiving chlorambucil alone or in combination with obinutuzumab or rituximab. Presented at: 21st Congress of the European Hematology Association; 2016 Jun 9–12; Copenhagen, Denmark.
   Google Scholar
• Merli M, Ferrario A, Maffioli M, et al. Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin’s lymphoma. Expert Opin Investig Drugs. 2015;24:897–912.
   PubMed Web of Science ®Google Scholar
• Aspeslagh S, Postel-Vinay S, Rusakiewicz S, et al. Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer. 2016;52:50–66.
   PubMed Web of Science ®Google Scholar
• Powderly JD, Gutierrez M, Wang D, et al. A phase 1b/2, open-label study to evaluate the safety and tolerability of MEDI6469 in combination with immune therapeutic agents or therapeutic mAbs in patients with selected advanced solid tumors or aggressive B-cell lymphomas. J Clin Oncol. 2015;33:suppl, abstract TPS3091.
   Web of Science ®Google Scholar
• Zulfiqar B, Mahroo A, Nasir K, et al. Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors. Onco Targets Ther. 2017;10:463–476.
   PubMed Web of Science ®Google Scholar
• Michaud HA, Eliaou JF, Lafont V, et al. Tumor antigen-targeting monoclonal antibody-based immunotherapy: orchestrating combined strategies for the development of long-term antitumor immunity. Oncoimmunology. 2014;3:e955684.
   PubMed Web of Science ®Google Scholar
• Vincent M, Teppaz G, Lajoie L, et al. Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse. MAbs. 2014;6:1026–1037.
   PubMed Web of Science ®Google Scholar
• Klein C, Waldhauer I, Nicolini VG, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. 2017;6:e1277306.
   PubMed Web of Science ®Google Scholar
• Rodgers DT, Mazagova M, Hampton EN, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A. 2016;113:E459–E468.
   PubMed Web of Science ®Google Scholar
• Kudo K, Imai C, Lorenzini P, et al. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res. 2014;74:93–103.
   PubMed Web of Science ®Google Scholar
• Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther. 2012;12:673–684.
   PubMed Web of Science ®Google Scholar
• Pievani A, Belussi C, Klein C, et al. Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. Blood. 2010;117:510–518.
   PubMed Web of Science ®Google Scholar
• Cheson BD. CLL and NHL: the end of chemotherapy? Blood. 2014;123:3368–3370.
   PubMed Web of Science ®Google Scholar